On June 25, 2026 GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, reported the closing of its previously announced equity financing with Samsung affiliates including Samsung C&T Corporation.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Pursuant to the definitive agreement, the Samsung entities invested $110 million in GRAIL through the purchase of shares of GRAIL common stock at a price of $70.05 per share, representing a long-term investment in support of GRAIL’s growth and international expansion objectives.
"This investment from the Samsung entities further strengthens our balance sheet and extends our cash runway as we advance key priorities, including securing regulatory approval and reimbursement for Galleri in the United States and expanding access to multi-cancer early detection internationally," said Aaron Freidin, Chief Financial Officer of GRAIL. "We are pleased to complete this financing and look forward to deepening our strategic collaboration with Samsung as we work to bring Galleri to patients in Asia."
As previously announced, GRAIL and Samsung C&T Corporation intend to collaborate to commercialize the Galleri multi-cancer early detection test in South Korea, with the potential to expand into additional Asian markets, including Japan and Singapore, subject to regulatory approvals and other conditions. Initial testing will continue to be performed at GRAIL’s clinical laboratory in Research Triangle Park, North Carolina.
"GRAIL is at a pivotal moment in its mission to transform early cancer detection. This investment in GRAIL, together with the strategic business collaboration, represents a significant milestone in advancing Samsung C&T’s vision expanding access to cancer early detection. We are excited to bring the benefits of innovative screening technologies to more people in South Korea and Asia, and believe this partnership will bring us one step closer to GRAIL and Samsung C&T’s shared goal of transforming cancer care through earlier detection," said Jaywoo Kim, Executive Vice President of Life Science Business at Samsung C&T.
Latham & Watkins LLP served as legal advisor and Morgan Stanley & Co. LLC served as financial advisor to GRAIL. Samsung was advised by Covington & Burling, BKL, and E&Y Han Young (Korea).
(Press release, Grail, JUN 25, 2026, View Source [SID1234668956])